404
+1-313-307-4176
Companion Diagnostics Market Report
Covid-19 has impacted the market dynamics, competition, and global supply chains. The revenues has gone down in 2020 and may resume an uptrend gradually form 2021. Companies optimizing their operation and statergy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
This report, from Stratview Research, studies the global clinical diagnostics market - companion diagnostics over the trend period of 2014 to 2017 and forecast period of 2018 to 2025. The report provides detailed insights into the market dynamics to enable informed business decision making and growth strategy formulation based on the opportunities present in the market.
The Burning Questions This Report Will Answer:
Companion diagnostics are considered as one of the most important tools for the implementation of personalized medicine. This enables the physician in identifying a specific biomarker that could indicate the patients most likely outcome-based combination of therapies or even specific treatment regimen.
InVentiv Health's survey (2017 by Jessica Lee, Ravi Patel, David Ruch and Katya Magonova) with practicing oncologists in the US predicted that 90% of the participating physician (n=30 out of total pool of 85) might accept a multi-biomarker diagnostic tool as the standard of care in the next three to five years. Can the results from 30 oncologists predict an accurate demand trend in the US market? But what about the other regions? What will be the adoption rate in the EU5, major markets such as China, Korea, Japan, Singapore and Australia?
Companion diagnostics that can help identify the right patient for the right drug at the right time are playing a major role in this trend. Companies like Astellas, Takeda, Astra Zeneca are making in-roads in this market. This report will help the reader look at the market from 360-degree view, while the in-depth demand analysis will help the manufacturer prioritize the right segment, the hurdles and issues faced by the manufacturers will also help the policy makers realize where to cap the price and where all to subsidize. The comprehensive study will encompass the demand and supply side of the market to help the reader get a complete top down approach of the companion diagnostic market.
Our reports offer high-quality insights and are the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. About 10 detailed primary interviews with the market players across the value chain in all four regions and industry experts have been executed to obtain both the qualitative and quantitative insights.
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:
The global clinical diagnostics market (IVD) is segmented into the following categories:
By Indication
By Technology
By Testing Facility
By Region
With this detailed report, Stratview Research offers one of the following free customization options to our first-time clients:
Company Profiling
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
WE ACCEPT
